JP2009149689A - ウイルスに用いる癌の処置および検出方法 - Google Patents

ウイルスに用いる癌の処置および検出方法 Download PDF

Info

Publication number
JP2009149689A
JP2009149689A JP2009077773A JP2009077773A JP2009149689A JP 2009149689 A JP2009149689 A JP 2009149689A JP 2009077773 A JP2009077773 A JP 2009077773A JP 2009077773 A JP2009077773 A JP 2009077773A JP 2009149689 A JP2009149689 A JP 2009149689A
Authority
JP
Japan
Prior art keywords
treatment
cancer
strain
ndv
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009077773A
Other languages
English (en)
Inventor
Robert M Lorence
エム． ローレンス ロバート
Kirk W Reichard
ダブリュ． レイチャード カーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of JP2009149689A publication Critical patent/JP2009149689A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

【課題】化学療法および放射線照射における最近の進歩に関わらず、癌が死因の上位に
位置する現在において、哺乳動物の癌を処置する方法において、医薬的に許容される担体
中でニューキャッスル病ウイルスの有効量を哺乳動物に投与することからなる方法を提供
すること。
【解決手段】哺乳動物の癌を処置する方法において、医薬的に許容される担体中でニュ
ーキャッスル病ウイルスの有効量を哺乳動物に投与することからなる方法および哺乳類動
物の癌を処置する方法において、ニューキャッスル病ウイルスを他の薬剤と併用し、その
両者をその併用が癌に対して有効である十分な量で哺乳類動物に投与することからなる方
法。
【選択図】なし

Description
図１は，無胸腺マウスにおけるＩＭＲ−３２ヒト神経芽腫異種移植片の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を例示する。 図２は無胸腺マウスにおけるＨＴ−１０８０線維肉腫異種移植片の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を示す。 図３は，無胸腺マウスにおけるＮＣｌ−Ｈ４６０ヒト大細胞肺癌異種移植片の生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を示す。 図４は，ＩＭＲ−３２ヒト神経芽腫異種移植片の，生存ＮＤＶ（７３−T株）全身性（腹腔内）注射後の退縮を示す。 図５は，比較的緩和なビレンスのＮＤＶ株（Ｍ，ＭａｓｓＭＫ１０７）の腫瘍退縮誘発における有効性を，比較的ビレンスの高いＮＤＶ株（７３−Ｔ）の場合とともに例示する。 図６は，無胸腺マウスにおけるＵ８７ＭＧヒトグリオブラストーマ異種移植片の生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を示す。 図７は無胸腺マウスにおけるＫＢ８−５−１１ヒト子宮頸部癌の生存ＮＤＶ（７３−T株）の腫瘍内注入後の増殖阻害を示す。 図８は，無胸腺マウスにおけるＰＣ−３ヒト前立腺癌の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を示す。 図９は無胸腺マウスにおけるＨＴ２９ヒト結腸癌の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の増殖阻害を示す。 図１０は無胸腺マウスにおけるＳＫ−ＢＲ−３ヒト乳癌の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の増殖阻害を示す。 図１１は，無胸腺マウスにおけるＳＷ６２０ヒト結腸癌の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の増殖阻害を示す。 図１２は，無胸腺マウスにおけるＮ四１７３８７ヒト結腸癌の，生存ＮＤＶ（７３−T株）の腫瘍内注入後の増殖阻害を示す。 図１３は，無胸腺マウスにおけるＴＨ１５１４５ヒト滑膜肉腫の生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を示す． 図１４は，無胸腺マウスにおけるＭＥＬ３３０ヒトメラノーマ異種移植片の生存ＮＤＶ（７３−T株）の腫瘍内注入後の退縮を示す。

Claims (1)

  1. 本明細書に記載の発明。
JP2009077773A 1993-04-30 2009-03-26 ウイルスに用いる癌の処置および検出方法 Withdrawn JP2009149689A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5551993A 1993-04-30 1993-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005087342A Division JP2005187484A (ja) 1993-04-30 2005-03-24 ウイルスに用いる癌の処置および検出方法

Publications (1)

Publication Number Publication Date
JP2009149689A true JP2009149689A (ja) 2009-07-09

Family

ID=21998395

Family Applications (3)

Application Number Title Priority Date Filing Date
JP52456394A Expired - Fee Related JP4338781B2 (ja) 1993-04-30 1994-04-29 ウイルスを用いる癌の処置および検出方法
JP2005087342A Withdrawn JP2005187484A (ja) 1993-04-30 2005-03-24 ウイルスに用いる癌の処置および検出方法
JP2009077773A Withdrawn JP2009149689A (ja) 1993-04-30 2009-03-26 ウイルスに用いる癌の処置および検出方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP52456394A Expired - Fee Related JP4338781B2 (ja) 1993-04-30 1994-04-29 ウイルスを用いる癌の処置および検出方法
JP2005087342A Withdrawn JP2005187484A (ja) 1993-04-30 2005-03-24 ウイルスに用いる癌の処置および検出方法

Country Status (12)

Country Link
US (2) US7056689B1 (ja)
EP (4) EP2009119A1 (ja)
JP (3) JP4338781B2 (ja)
AT (3) ATE411809T1 (ja)
AU (1) AU699487B2 (ja)
CA (1) CA2161671A1 (ja)
DE (3) DE69435118D1 (ja)
DK (3) DK1314431T3 (ja)
ES (3) ES2315595T3 (ja)
HK (1) HK1052871A1 (ja)
PT (3) PT1486211E (ja)
WO (1) WO1994025627A1 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009119A1 (en) * 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
IL135507A0 (en) * 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
FR2788099B1 (fr) 1999-01-06 2001-02-09 Vallourec Mannesmann Oil & Gas Assemblage filete de deux tubes metalliques a couple eleve de vissage
JP2003530301A (ja) * 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
HK1052950B (en) 2000-06-26 2005-06-24 Wellstat Biologics Corporation Purging of cells using viruses
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
EP1385466B1 (en) 2001-05-11 2011-03-09 Wellstat Biologics Corporation Oncolytic virus therapy
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) * 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
NZ537255A (en) 2002-06-21 2009-04-30 Wellstat Biologics Corp Administration of therapeutic viruses
AU2003287472A1 (en) * 2002-11-05 2004-06-03 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060099189A1 (en) * 2003-03-24 2006-05-11 Lorence Robert M Anti-cancer virus desensitization method
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
US20060018884A1 (en) * 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
ATE540698T1 (de) * 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
KR101492643B1 (ko) 2005-12-02 2015-02-12 이칸 스쿨 오브 메디슨 엣 마운트 시나이 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
JP5547640B2 (ja) * 2008-09-16 2014-07-16 ジェノミディア株式会社 前立腺癌の治療・予防剤
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
EA038981B1 (ru) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
CN121343934A (zh) 2017-05-10 2026-01-16 制药五有限责任公司 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577525A (en) 1964-07-01 1971-05-04 Cornell Res Foundation Inc Adenovirus vaccine against canine hepatitis
NL7111160A (ja) 1971-03-09 1972-09-12
ZA754725B (en) 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
JPS5173117A (en) * 1974-12-19 1976-06-24 Handai Biseibutsubyo Kenkyukai Ganryohozaino seiho
US4108983A (en) 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US4126671A (en) 1976-08-17 1978-11-21 Pitman-Moore, Inc. Method for detecting bovine leukemia viral infection
US4379839A (en) 1977-05-23 1983-04-12 The Trustees Of Columbia University In The City Of New York Method for detecting cancer
IT1117218B (it) 1979-05-18 1986-02-17 Depa Sas Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto
US4282315A (en) 1979-09-13 1981-08-04 Corning Glass Works Preparation of enriched whole virus radioligand
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4465769A (en) 1981-12-11 1984-08-14 The United States Of America As Represented By The Department Of Health And Human Services Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
US4582787A (en) 1982-12-30 1986-04-15 Frankel Jack W Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
JPS6089755A (ja) 1983-07-01 1985-05-20 フイリツプ・ジヨン・ベア−ド 診断用試薬及びその製造法並びにそれを用いる診断法
US4647773A (en) 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS60249058A (ja) 1984-05-25 1985-12-09 Eisai Co Ltd Ａｔｌウイルス抗体の測定方法および試薬
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
US5075213A (en) 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
FR2593828B2 (fr) 1986-01-31 1990-05-04 Pasteur Institut Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
US4735895A (en) 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US4786590A (en) 1985-01-15 1988-11-22 California Institute Of Technology Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
GB8500918D0 (en) 1985-01-15 1985-02-20 Cancer Res Inst Viral isolates
US4970071A (en) 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0252940A4 (en) 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Anti-sense rna for treatment of retroviral disease states.
AU602875B2 (en) 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4861720A (en) 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
DE68929343T2 (de) 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5077198A (en) 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5057314A (en) 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
FR2639225B1 (fr) 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
US5169753A (en) 1989-06-05 1992-12-08 Genelabs Incorporated Method and kit for detecting human retrovirus
FR2656627B1 (fr) 1989-12-28 1992-04-17 Pasteur Institut Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5195539A (en) * 1992-03-23 1993-03-23 Minnesota Mining And Manufacturing Company Earplug compression device
CA2132328C (en) 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
ATE199568T1 (de) 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
JPH08508641A (ja) 1993-03-16 1996-09-17 ブリテイツシユ・テクノロジー・グループ・リミテツド ウイルスタンパク質による免疫応答刺激
EP2009119A1 (en) * 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU2003287472A1 (en) * 2002-11-05 2004-06-03 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN4003003597, Ｊ．Ｓｕｒｇ．Ｒｅｓ．, 1992, ５２（５）, ４４８−４５３ *
JPN4003003598, Ｊ． Ｎａｔｌ． Ｃａｎｃｅｒ Ｉｎｓｔ．, 1988, ８０（１６）, １３０５−１３１２ *
JPN4006019207, ＣＡＮＣＥＲ ＲＥＶ．, 1986, ＶＯＬ．５, １９−４９ *
JPN4006019208, ＮＥＷ ＥＮＧＬ． Ｊ． ＭＥＤ．, 1964, ２７１（１３）, ６４５−６５１ *
JPN4006019209, ＩＮＴ． Ｊ． ＣＡＮＣＥＲ, 1986, ３７（４）, ５６９−５７７ *
JPN4006019210, Ｊ． ＮＡＴＬ． ＣＡＮＣＥＲ ＩＮＳＴ．, 1990, ８２（３）, ２１３−２１７ *

Also Published As

Publication number Publication date
EP1314431A3 (en) 2003-06-18
DE69432409D1 (de) 2003-05-08
EP0696326A4 (en) 1997-08-20
JP4338781B2 (ja) 2009-10-07
ATE411809T1 (de) 2008-11-15
EP0696326B1 (en) 2003-04-02
ATE401092T1 (de) 2008-08-15
PT1314431E (pt) 2008-10-24
DK1486211T3 (da) 2009-01-19
DE69435118D1 (de) 2008-08-28
AU6821394A (en) 1994-11-21
DE69432409T2 (de) 2003-12-24
EP2009119A1 (en) 2008-12-31
ES2196026T3 (es) 2003-12-16
DK0696326T3 (da) 2003-06-23
EP1314431A2 (en) 2003-05-28
ES2315595T3 (es) 2009-04-01
EP1486211A1 (en) 2004-12-15
EP1314431B1 (en) 2008-07-16
CA2161671A1 (en) 1994-11-10
US7736640B2 (en) 2010-06-15
PT1486211E (pt) 2009-02-02
AU699487B2 (en) 1998-12-03
JPH09503995A (ja) 1997-04-22
DK0696326T5 (da) 2003-07-14
ATE236271T1 (de) 2003-04-15
DE69435155D1 (de) 2008-12-04
EP1486211B1 (en) 2008-10-22
EP0696326A1 (en) 1996-02-14
US20060216310A1 (en) 2006-09-28
US7056689B1 (en) 2006-06-06
JP2005187484A (ja) 2005-07-14
DK1314431T3 (da) 2008-11-10
HK1052871A1 (en) 2003-10-03
WO1994025627A1 (en) 1994-11-10
ES2310580T3 (es) 2009-01-16
PT696326E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
JP2009149689A (ja) ウイルスに用いる癌の処置および検出方法
Rudnicki et al. Paraneoplastic syndromes of the spinal cord, nerve, and muscle
Qiao et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
Tfelt-Hansen Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials
NO971355D0 (no) Fotodynamiske terapi i slektiv celleinaktivering i blod og behandling av immundysfunksjons-sykdommer
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
ATE361069T1 (de) Phytochemikalien zur behandlung von mastalgie und endometriose
CR6458A (es) Composiciones de valdecoxib
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
EP0957925A4 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
DE69925251D1 (de) Zusammensetzungen enthaltend isovalerianamide zusammen mit ibuprofen
Sokolov et al. Photodynamic therapy (PDT) of malignant tumors by photosensitzer photosens: results of 45 clinical cases
Parker et al. Aquagenic urticaria
US20040091458A1 (en) Method for reducing pain using oncolytic viruses
Roger et al. Pharmacological modulation of postprandial colonic motor activity in the pony
SE8204288D0 (sv) Apap-anticidum-komposition
EA200000686A1 (ru) Препараты левозимендана, предназначенные для введения через слизистую оболочку
DE3872213D1 (de) 5-substituierte ornithin-derivate.
Marschke et al. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer
RU97112236A (ru) Способ лечения злокачественных опухолей кости и метастазов в кость остеолитического характера
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
Adaikan et al. Oral trazodone in the treatment of total secondary impotence in a diabetic patient
Stewart Treatment of coprophagia with carbamazepine.
RU97105092A (ru) Способ диагностики рака пищевода

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110228